Ortho Dermatologics gets FDA green light for Arazlo
Bausch Health's Ortho Dermatologics unit has received the Food and Drug Administration’s blessing for Arazlo (tazarotene) lotion, 0.045%, for the topical treatment of acne vulgaris in patients nine years of age and older.
Arazlo is the first tazarotene acne treatment available in a lotion form, and has been shown to provide strong efficacy with favorable tolerability.
"Today's approval of Arazlo showcases our continued commitment to expanding our acne portfolio to help the approximately 50 million Americans who are impacted by this prevalent skin condition," said Bill Humphries, Ortho Dermatologics president. "As our fourth FDA approval in just 14 months, Arazlo will provide dermatologists the efficacy expected of tazarotene in a new formulation that helps minimize the dryness and irritation historically associated with tazarotene use, which can cause many acne patients to discontinue treatment. We are purposely timing the launch of Arazlo to coincide with the start of acne season in the first half of 2020."